Huadong Medicine’s DR30206 Approved for Clinical Trials in Gastrointestinal Tumors
China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval...
Beijing Unveils Measures to Accelerate Innovative Drug Development and Regulatory Efficiency
The Beijing Municipal Medical Insurance Bureau, in collaboration with seven other bureaus, has released the...
Novo Nordisk Partners with Tencent Healthcare for Weight Management Initiative in China
In alignment with China’s “Weight Management Year” initiative, Denmark-based Novo Nordisk A/S (NYSE: NVO) has...
Siemens Set to Acquire Dotmatics for $5.1 Billion to Boost Life Sciences R&D
German industrial giant Siemens AG (ETR: SIE) has announced plans to acquire US-based Dotmatics, a...
Lynmou Medical Secures Series A Funding for Endoscope Expansion
Lynmou Medical, a Hangzhou-based provider of soft endoscope solutions, has reportedly secured “tens of millions”...
Phanes Therapeutics Gains CDE Approval for Peluntamig Phase II Trial in SCLC and NEC
Sino-US biotech Phanes Therapeutics Inc. announced receiving approval from the Center for Drug Evaluation (CDE)...
Hengrui Pharmaceuticals Licenses SHR7280 to Merck for Assisted Reproduction
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has entered into a licensing agreement with...
Suzhou Ribo Life Science Completes Enrollment for Phase IIa Study of FXI-Targeted siRNA Drug RBD4059
China-based Suzhou Ribo Life Science Co., Ltd announced the completion of subject enrollment for the...
Nanjing King-Friend Bio’s Biosimilar Victoza Approved by FDA
China-based Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SHA: 603707) announced that its Abbreviated New Drug...
Bio-Sincerity Pharma-tech Gains NMPA Approval for BIOS-0618 in Obstructive Sleep Apnea
Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) has secured clinical trial approval from China’s National...
Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline
China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial...
Santen’s Tapcom Approved by China’s NMPA for Glaucoma Treatment
Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from China’s National...
Peijia Medical’s ReachTactile Robot Assists First Human TAVR Trial
China’s Peijia Medical Ltd (HKG: 9996) has announced the successful treatment of the first patient...
Enhertu Approved by EC for Earlier-Line Treatment of HR+/HER2-low Breast Cancer
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that they have received approval...
Sino Biopharmaceutical’s TQB2101 Receives NMPA Approval for Phase I Trial in Advanced Malignancies
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the National...
Hengrui Pharmaceuticals Gains NMPA Approval for HRS-6719 in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical trial...
Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Rare Diseases
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received Orphan Drug Designation (ODD) from...
Sunshine Guojian’s SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG:...
Sarepta and Roche Seek to Resume Elevidys Trials After EMA Halt
The European Medicines Agency (EMA) may lift the temporary hold on certain Phase III studies...
Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3Kα Inhibitor
German pharmaceutical giant Bayer’s (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the...